Bioxel Pharma Inc.

Bioxel Pharma Inc. announced it has extended its marketing presence in Asia through the execution of letters of intent with two major Korean generic drug companies for docetaxel active pharmaceutical ingredients. Each of these companies achieves sales of over $1 billion on an annualized basis. The names of the companies and the terms of these agreements have not been disclosed for proprietary reasons. Working with its regional marketing representative, Bioxel is actively securing customers for its newest taxane offering in this strategic region.